Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089600 | 0.99 | LTA4H (0.56) | HRH3LTA4HMAOBPSMB1PSMB5 | |
| SCHEMBL29953914 | 0.87 | PSMB1 (0.64) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL3125089 | 0.87 | PSMB1 (0.64) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL2966068 | 0.85 | PSMB1 (0.61) | HRH3LTA4HPSMB1PSMB5PSMB2 | |
| SCHEMBL29957497 | 0.84 | BACE1 (0.62) | HRH3LTA4HKDM4EPOLB | |
| SCHEMBL29957034 | 0.84 | BACE1 (0.62) | HRH3LTA4HKDM4EPOLB | |
| SCHEMBL29951665 | 0.83 | LTA4H (0.61) | LTA4HKDM4EPOLB | |
| SCHEMBL30186207 | 0.81 | HRH3 (0.81) | HRH3LTA4HMAOB | |
| SCHEMBL11151279 | 0.81 | HRH3 (0.81) | HRH3LTA4HMAOB | |
| SCHEMBL29955521 | 0.80 | HRH3 (0.69) | HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | HRH3 2504/4885LTA4H 2426/4885MAOB 3587/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | HRH3 2769/4885LTA4H 2448/4885MAOB 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.